| Literature DB >> 31166033 |
Peeyush N Goel1,2, Yasaman Moharrer1,2, John H Hebb1,2,3, Alexander J Egol1,2, Gurpreet Kaur4, Kurt D Hankenson5, Jaimo Ahn1,2, Jason W Ashley6.
Abstract
Owing to the central role of osteoclasts in bone physiology and remodeling, manipulation of their maturation process provides a potential therapeutic strategy for treating bone diseases. To investigate this, we genetically inhibited the Notch signaling pathway in the myeloid lineage, which includes osteoclast precursors, using a dominant negative form of MAML (dnMAML) that inhibits the transcriptional complex required for downstream Notch signaling. Osteoclasts derived from dnMAML mice showed no significant differences in early osteoclastic gene expression compared to the wild type. Further, these demonstrated significantly lowered resorption activity using bone surfaces while retaining their osteoblast stimulating ability using ex vivo techniques. Using in vivo approaches, we detected significantly higher bone formation rates and osteoblast gene expression in dnMAML cohorts. Further, these mice exhibited increased bone/tissue mineral density compared to wild type and larger bony calluses in later stages of fracture healing. These observations suggest that therapeutic suppression of osteoclast Notch signaling could reduce, but not eliminate, osteoclastic resorption without suppression of restorative bone remodeling and, therefore, presents a balanced paradigm for increasing bone formation, regeneration, and healing.Entities:
Keywords: Notch signaling; bone formation; fracture healing; osteoblasts; osteoclasts; regeneration
Mesh:
Substances:
Year: 2019 PMID: 31166033 PMCID: PMC6739141 DOI: 10.1002/jor.24384
Source DB: PubMed Journal: J Orthop Res ISSN: 0736-0266 Impact factor: 3.494